Overview

Efficacy of Sodium Polystyrene Sulfonate in the Treatment of Hyperkaliemia in Pre-dialysis Patients

Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to determine if sodium polystyrene sulfonate (SPS) is an effective treatment of mild hyperkalemia in chronic kidney disease patients followed at a pre-dialysis or nephrology outpatient clinic. Subjects will be randomized to one of two treatment arms: 30 g of placebo or SPS to be taken orally once daily for seven days. The change in serum potassium levels will be compared in both treatment groups. The proportion of subjects attaining normokalemia (3.5 to 5.0 mmol/L) after seven days of treatment will also be compared. Finally, side effects will be reported for each treatment arm.
Phase:
Phase 4
Details
Lead Sponsor:
Maisonneuve-Rosemont Hospital
Collaborators:
Department of Pharmacy, Maisonneuve Rosemont Hospital
Nephrology Research Axis of Maisonneuve Rosemont Hospital
Université de Montréal
Treatments:
Polystyrene sulfonic acid